pazopanib teva 400 mg film - coated tablets
400 mg film - coated tablets
pazopanib zentiva 200 mg film - coated tablets
200 mg film - coated tablets
pazopanib zentiva 400 mg film - coated tablets
400 mg film - coated tablets
pazopanib g.l. pharma 200 mg film - coated tablets
200 mg film - coated tablets
pazopanib g.l. pharma 400 mg film - coated tablets
400 mg film - coated tablets
pazopanib accord 200 mg film- coated tablets
200 mg film- coated tablets
pazopanib accord 400 mg film- coated tablets
400 mg film- coated tablets
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. Вижте раздели 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.